CNC — Deck
Centene is America's largest Medicaid managed care company, collecting $195 billion in annual premiums from federal and state government programs to manage healthcare for 28 million low-income and underinsured members.
Medicaid HBR is the entire thesis — and it resolves in three days.
- The one ratio. Medicaid HBR improved 190 bps from 94.9% in Q2 2025 to 93.0% in Q4 2025 on a $124B premium base. Every 100 bps of improvement releases roughly $1.2B in pre-tax earnings — approximately $2 per share. Whether this trajectory continues into 2026 determines if CNC is a turnaround or a value trap.
- The rate catch-up. States granted a composite 5.5% Medicaid rate increase in FY2025 against mid-six medical cost trend — rates were still underwater. For 2026, management expects mid-fours net trend, meaning rates would exceed costs for the first time since redeterminations began. The margin payoff lags by 12-18 months.
- April 28. Q1 2026 earnings in three days. Consensus expects $2.12 EPS on $47.6B revenue, but the only number that matters is Medicaid HBR. Below 93% confirms the recovery is structural. Above 93.5% suggests Q4 was seasonal and the full-year $3+ guidance is at risk.
The cheapest large-cap MCO in a generation — but margins explain the discount.
Centene produces more revenue than Elevance and roughly matches Cigna but trades at one-sixth of either market cap. The gap reflects a structural margin deficit: CNC earns 1-2% operating margins where peers earn 3-8%, and Molina runs the same Medicaid business at one-quarter the scale with double the margins. If margins recover to the 2% level achieved in FY2024, the stock re-rates toward $50-65; if they don't, the discount is permanent.
Three decades of acquisitions, one year of reckoning.
The empire. Under founding CEO Michael Neidorff, Centene grew from a regional Medicaid specialist into a $145B revenue empire through serial acquisitions — Health Net (2016), Fidelis Care (2018), WellCare ($17.3B, 2020), and Magellan Health (2022). Revenue grew sixfold in seven years, but operating margins compressed from 3% to under 1% — scale never translated to profitability.
The pivot. Activist Politan Capital forced a board overhaul in 2022, installing Sarah London as CEO, who launched a simplification campaign: 10+ divestitures, 70% real estate reduction, SG&A cut from 9.7% to 7.4%. By FY2024, adjusted EPS had climbed to $7.17 and the thesis appeared vindicated. Then in July 2025, Centene withdrew full-year guidance after an actuarial review revealed a $1.8B Marketplace morbidity deficit, and the stock crashed 40% in a single session.
The wreckage. FY2025 delivered a $6.7B goodwill impairment — management's admission that 40% of acquisition-era value was illusory — adjusted EPS of $2.08 (down 71%), and an active securities fraud class action. CEO London bought 19,230 shares at $25.50 near the trough; David Einhorn's Greenlight Capital accumulated 2.6M shares, calling CNC a 'coiled spring.' Goldman Sachs rates it Sell at $32; Barclays and Bernstein rate it Buy at $54-59.
Lean cautiously bullish — but wait for April 28.
- For. At 0.11× P/S and a 21% FCF yield, CNC is priced for permanent margin impairment. The company generated $5.1B in operating cash flow in FY2025 — a year with negative net income — and ended the year in a net cash position ($17.9B cash vs $17.5B debt). The Q2-to-Q4 HBR trajectory does not support the permanent-impairment thesis.
- For. Each 100 bps of Medicaid HBR improvement on $124B of premiums releases $1.2B pre-tax — roughly $2/share. Getting from 93.7% back to the 91-92% pre-redetermination baseline would add $2-3B in annual pre-tax income. The operating leverage at this revenue scale is asymmetric at $42.
- Against. Management guided FY2025 at $7.25 EPS and delivered $2.08 — a 71% miss, the worst in MCO history. Insider ownership is 0.31%. The long-term EPS growth target was quietly abandoned. Credibility will take quarters to rebuild.
- Against. Marketplace membership is contracting 30% as ACA subsidies expire, with the remaining pool skewing sicker. The Bronze-heavy repricing strategy is untested at this scale. And Medicaid faces a second wave of member attrition from work requirements taking effect January 2027.
Watchlist to re-rate: Q1 2026 Medicaid HBR (April 28); Marketplace margin under post-EAPTC enrollment mix (Q2 results, late July); OBBBA Medicaid work requirement implementation (effective January 2027).